High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance

Autor: José A. García-Marco, Javier López Jiménez, Valle Recasens, Miguel Fernández Zarzoso, Eva González-Barca, Nieves Somolinos De Marcos, M. Jose Ramírez, Francisco Javier Peñalver Parraga, Lucrecia Yañez, Javier De La Serna Torroba, Maria Dolores Garcia Malo, Guillermo Deben Ariznavarreta, Ernesto Perez Persona, M. Angeles Ruiz Guinaldo, Raquel De Paz Arias, Elena Bañas Llanos, Isidro Jarque, M. del Carmen Fernandez Valle, Ana Carral Tatay, Jaime Perez De Oteyza, Eva Maria Donato Martin, Inmaculada Perez Fernández, Rafael Martinez Martinez, M. Angeles Andreu Costa, Diana Champ, Julio García Suarez, Marcos González Díaz, Secundino Ferrer, Félix Carbonell, José A. García-Vela

Publikováno v: Haematologica, Vol 104, Iss 11 (2019)

It has been postulated that monitoring measurable residual disease (MRD) could be used as a surrogate marker of progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) patients after treatment with immunochemotherapy regimens. In this s

Externí odkaz: https://doaj.org/article/fb9a08ed52534cc49c34466240ad698c

A randomized phase II study comparing consolidation with a single dose of

Autor: Armando, López-Guillermo, Miguel Ángel, Canales, Ivan, Dlouhy, Santiago, Mercadal, Javier, Briones, Alejandro, Martín García-Sancho, Juan Manuel, Sancho, José María, Moraleda, María José, Terol, Antonio, Salar, Luis, Palomera, Santiago, Gardella, Isidro, Jarque, Secundino, Ferrer, Joan, Bargay, Andrés, López, Carlos, Panizo, Anna, Muntañola, Carlos, Montalbán, Eulogio, Conde, Miguel T, Hernández, Alfons, Soler, José A, García Marco, Guillermo, Deben, Julián, Marín, José Francisco, Tomás

Publikováno v: Leukemialymphoma. 63(1)

This is a randomized phase-2 trial aimed to compare consolidation vs. maintenance in untreated patients with follicular lymphoma (FL) responding to induction. 146 patients were enrolled from 25 Spanish institutions (ZAR2007; ClinicalTrials.gov #NCT00

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3157e7aeddbb91b36ad9d90f08f84c34
https://pubmed.ncbi.nlm.nih.gov/34459702

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study

Autor: Alejandro Martín, Eulogio Conde, Montserrat Arnan, Miguel A. Canales, Guillermo Deben, Juan M. Sancho, Rafael Andreu, Antonio Salar, Pedro García-Sanchez, Lourdes Vázquez, Sara Nistal, María-José Requena, Eva M. Donato, José A. González, Ángel León, Concepción Ruiz, Carlos Grande, Eva González-Barca, María-Dolores Caballero

Publikováno v: Haematologica, Vol 93, Iss 12 (2008)

Background The role of re-treatment with rituximab in aggressive B-cell lymphomas still needs to be defined. This study evaluated the influence of prior exposure to rituximab on response rates and survival in patients with diffuse large B-cell lympho

Externí odkaz: https://doaj.org/article/c8e4e78a815b4aa99201d4747787f914

Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma

Autor: Carlos Grande, Guillermo Deben, Elena Pérez Ceballos, Maria-Victoria Mateos, Felipe Casado, Juan José Lahuerta, Javier Loscertales, Santiago Osorio, Jose Luis Sastre, María Teresa Olave, Asunción Peña, Asunción Echeveste, Julio Delgado, Antonio Salar, Adolfo de la Fuente, Javier de la Rubia, Francisco Javier Peñalver

Publikováno v: European Journal of Haematology. 96:532-540

Bendamustine is an increasingly used hybrid alkylating agent that is active in lymphoid neoplasias via a novel mechanism of action. There are some pending questions about its use in clinical practice because of its developmental features. A consensus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85369e090e91b60286f0c075acc70945
https://doi.org/10.1111/ejh.12633

Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line

Autor: Antonio Almeida, Haifa Kathrin Al-Ali, Dietmar Geissler, Joan Bargay, Arjan A. van de Loosdrecht, Peter Krippl, Guillermo Deben, Sylvain Thepot, Raphael Itzykson, Ana Garrido, Richard Greil, Alois Lang, Eva Maria Autzinger, Jaime L. Wetzel, Lisa Pleyer, Pierre Fenaux, Reinhard Stauder, Ricardo Pinto, Peter Valent, Fernando Ramos, Mikkael A. Sekeres, Wolfgang R. Sperr, Jose F Falantes, Lionel Ades, María Díez-Campelo, Pellegrino Musto, Santiago Bonanad, Jamile M. Shammo, Thomas Prebet, Luca Maurillo, Maria Joao Costa, Sonja Burgstaller, Susana Esteves, Carmen Pedro

Publikováno v: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
International Journal of Molecular Sciences; Volume 18; Issue 4; Pages: 837
International Journal of Molecular Sciences, 18(4):837. Multidisciplinary Digital Publishing Institute (MDPI)
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Almeida, A M, Prebet, T, Itzykson, R, Ramos, F, Al-Ali, H, Shammo, J, Pinto, R, Maurillo, L, Wetzel, J, Musto, P, Van De Loosdrecht, A A, Costa, M J, Esteves, S, Burgstaller, S, Stauder, R, Autzinger, E M, Lang, A, Krippl, P, Geissler, D, Falantes, J F, Pedro, C, Bargay, J, Deben, G, Garrido, A, Bonanad, S, Diez-Campelo, M, Thepot, S, Ades, L, Sperr, W R, Valent, P, Fenaux, P, Sekeres, M A, Greil, R & Pleyer, L 2017, ' Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line : A retrospective multinational study ', International Journal of Molecular Sciences, vol. 18, no. 4, 837 . https://doi.org/10.3390/ijms18040837
International Journal of Molecular Sciences
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica

Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelody

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4be8b172b8ff6838e83435a8bef686ba
https://doi.org/10.3390/ijms18040837